Localized Scleroderma (Morphea): Evaluation and Management
Treatment Approach
For active, potentially disfiguring or disabling localized scleroderma, treat with methotrexate 15 mg/m²/week (oral or subcutaneous) combined with systemic corticosteroids as bridge therapy for the first 3 months, and continue methotrexate for at least 12 months after achieving clinical improvement. 1
Disease Severity Stratification
Management depends critically on disease subtype and severity:
Limited/Superficial Disease (Circumscribed Morphea)
- Topical therapy first-line: Mid-to-potent topical corticosteroids 2
- Alternative topical options: Tacrolimus, calcipotriol, or imiquimod 1, 3
- Phototherapy: Medium-dose UVA1 for improving skin softness in isolated lesions (Level 1b evidence) 1
- These forms are generally of cosmetic concern only and do not require systemic treatment 1
Severe/Deep Disease (Linear, Generalized, Pansclerotic)
This is where aggressive treatment prevents irreversible morbidity:
First-line systemic therapy (100% expert agreement) 1:
- Methotrexate 15 mg/m²/week (oral or subcutaneous)
- Plus systemic corticosteroids during first 3 months as bridge therapy
- Either oral prednisone 1-2 mg/kg/day for 2-3 months with taper
- Or IV methylprednisolone pulses (30 mg/kg)
- This combination is supported by the only randomized controlled trial in this population 1
Duration: Continue methotrexate for minimum 12 months after achieving acceptable clinical improvement before tapering 1. Prolonged remission off medication is more likely with this extended treatment duration.
Refractory or Intolerant Cases
Second-line therapy: Mycophenolate mofetil 500-1000 mg/m² 1, 2
- Use when methotrexate fails, disease relapses, or patient is MTX-intolerant
- Retrospective data shows clinical improvement in all severe refractory cases with good safety profile 1
Third-line options (limited evidence):
- Mycophenolic acid 2
- Abatacept 2
- Biologics (TNF or IL-6 inhibitors) for resistant or CNS disease 1
- Emerging: Topical roflumilast 0.3% cream under occlusion showed rapid improvement in treatment-refractory cases within 6-12 weeks 4
Critical Evaluation Components
At Diagnosis and Follow-up
- Assess disease activity vs. damage: Use validated tools like LoSCAT (Localized Scleroderma Cutaneous Assessment Tool) 1, 3
- Determine lesion depth: Superficial dermal vs. deep (fascia, muscle, bone involvement)
- Identify subtype: Circumscribed, linear, generalized, pansclerotic, or mixed
- Screen for extracutaneous involvement: Joint contractures, limb length discrepancy, facial hemiatrophy, neurological complications (especially with linear subtypes)
Referral Indication
Given disease rarity (3.4 cases per million children/year), refer suspected cases to specialized pediatric rheumatology or dermatology centers for assessment and treatment 1. This concentrates expertise and improves outcomes.
Common Pitfalls to Avoid
Undertreating severe disease: Linear, generalized, and pansclerotic forms cause significant physical and psychological morbidity—treat aggressively from onset 1
Stopping treatment too early: Must continue methotrexate for ≥12 months after remission to prevent relapse 1. Consider withdrawal only after patient is in remission and off steroids for at least 1 year 1
Using phototherapy in children without considering long-term risks: While UVA1 is effective, prolonged maintenance leads to high cumulative radiation doses with risks of skin aging and carcinogenesis 1
Misclassifying disease severity: Circumscribed morphea can be managed topically, but linear/deep forms require systemic therapy to prevent irreversible damage 1
Safety Considerations
Methotrexate is well-tolerated in pediatric populations with low rates of non-severe side effects (nausea, headache, transient hepatotoxicity) 1. The evidence base for this regimen includes the only double-blind placebo-controlled trial in this condition, providing Level 1b evidence 1.
The 2024 German guideline 2 and 2019 consensus recommendations 1 align on this treatment algorithm, representing the most current expert consensus based on available evidence.